Key Takeaways
- Revenue crosses INR 1,000 crore milestone: Domestic business surged 22% YoY, driving the company past the quarterly sales landmark for the first time, while international business remained flattish.
- Profitability sharply improved: EBITDA margin expanded 190 bps to 29%, fueled by better product mix and disciplined overhead control, prompting management to guide toward the higher end of its margin band.
- CDMO business hit a seasonal air pocket: A weak global cough and cold season made for a muted quarter, but the order book signals a stronger second half.
- Ophthalmology integration is on track: The acquired portfolio is scaling smoothly, with the field force expanded and the annualized run rate expected to reach Rs. 180 crore+.
- What to watch next quarter: Whether the promised H2 CDMO recovery materializes in order inflow, the pace of the South Africa business turnaround, and the launch trajectory of the new in-licensed Novartis product.
Domestic Business Performance
- Broad-based growth: The 22% domestic growth was powered by a 300 bps volume outperformance versus the Indian pharmaceutical market, driven by the chronic portfolio and big brand franchises like Cilacar, Cilacar-T, Razel, and Metrogyl. Excluding the newly acquired Ophthalmology portfolio, organic growth was a healthy 13%.
- Metrogyl and Rantac resilience: Metrogyl delivered strong volume growth without the benefit of any WPI price increase passed on, while Rantac demand stabilized after a subdued period. Both brands continue to hold significant market share.
- Azmarda finds its floor: The market has consolidated to the top 4-5 players, with J.B. Pharma among the top 3. The brand has achieved a steady-state demand of 120,000-125,000 units per month, and management expects only double-digit volume growth from here on.
- New launches as a growth lever: The company is launching one or two products every two months in pediatrics, GI, and probiotics, including a new topical application for the Metrogyl franchise. These new products are contributing 2-3% to overall growth.
- Diabetes portfolio a non-event: Vildagliptin and Sitagliptin did not perform well, and the Dapagliflozin run rate is a modest ~Rs. 15 crore annually. Management has no big plans for the metabolics segment.
Chopra: "we want to grow the profits better than the topline and basically create value for all our stakeholders and build our organization which is more progressive and future ready."
Margin & Cost Structure
- The margin walk: A 190 bps EBITDA margin expansion to 29% was built on an 80 bps gross margin improvement (to 66.2%) and a 130 bps reduction in other expenses. The gross margin gain came from a better product mix skewed toward chronic therapies, strong Russia/CIS supply performance, and cost benefits, which more than offset the dilutive impact of the Ophthalmology portfolio.
- Overhead discipline: The 130 bps improvement in other expenses was a direct result of a focused optimization of overhead and marketing spends. This was achieved despite freight costs remaining elevated due to geopolitical issues.
- Balance sheet strength: Gross debt was slashed from Rs. 357 crore to Rs. 108 crore, turning the company net cash positive to the tune of Rs. 313 crore. Management expects to repay all remaining debt by March FY25 in equal quarterly installments, which will bring the interest cost down to ~Rs. 3 crore in Q2.
- Gross margin outlook: Management expects to maintain a gross margin in the 65%-66% range going forward.
Chopra: "what we want to also comment that our overall EBITDA margins would be on the higher side of the guidance that we are giving to the market."
International Business & CDMO
- A tale of two segments: The international business was flattish overall, masking a sharp divergence. Formulations excluding South Africa grew 9% YoY, with Russia and the Rest of the World delivering robust growth. The drag came entirely from South Africa, where the tender business has taken a ~Rs. 150 crore haircut over the last five quarters.
- CDMO seasonality bites: The CDMO business had a muted quarter due to a weak global cough and cold season. However, management pointed to stronger order books for Q3 and Q4, with new projects ongoing and a realization momentum expected to begin from H2 starting September. Double-digit growth is still the full-year expectation.
- South Africa turnaround bet: Management expects the South Africa business to begin recording growth in H2, with mid-teen growth anticipated from Q2 onwards. However, when asked about the margin benefit from this recovery, management deflected, noting that at Rs. 250 crore (~5% of revenue), the improvement would not be significant.
- International growth trajectory: Overall, double-digit growth for the international business is expected only from Q3 onwards, once the South Africa recovery and CDMO momentum converge.
Ophthalmology & Strategic Bets
- Integration proceeding smoothly: The Ophthalmology portfolio transition has been seamless. The field force has been expanded from ~70 to ~105 representatives, and secondary demand is showing positive traction. The annualized run rate is expected to move from Rs. 160 crore to Rs. 180 crore+, with new product introductions planned from H2.
- Inclisiran in-licensing: J.B. Pharma is one of only three companies in India chosen by Novartis to in-license Inclisiran, a novel therapy for LDL and triglyceride lowering. The cost of therapy is ~Rs. 3 lakh per year, with a dosing schedule of an injection on day one, month three, and then every six months. No specific launch timeline was provided.
- Lozenges pipeline building: The lozenges portfolio is progressing on multiple fronts. Immunity and wellness lozenges have started going to four countries in Europe. Melatonin lozenges are expected in the Middle East and Southeast Asia by year-end, Ibuprofen pain lozenges by mid-FY25, and branded lozenges for the US by Q4 FY25.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Operating EBITDA margin | On the higher side of the 26% to 28% guidance band | FY25 |
| Domestic business growth | Mid-teens (12-14%), outperforming the IPM (8-10%) | FY25 |
| CDMO growth | Double-digit growth, with realization momentum from H2 | FY25 |
| South Africa business | Mid-teen growth | From Q2 onwards |
| International business overall | Double-digit growth | From Q3 onwards |
| Ophthalmology portfolio run rate | Rs. 180 crore+ annualized | FY25 |
| Debt repayment | Repay all remaining debt (~Rs. 108 crore) in equal quarterly installments | By March FY25 |
| Gross margin | Maintain 65%-66% range | Going ahead |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue | ₹1,004 cr, +12% YoY |
| Domestic revenue | ₹595 cr, +22% YoY |
| International revenue | ₹409 cr, flat YoY |
| CDMO revenue | ₹106 cr, muted due to weak cough and cold season |
| Gross margin | 66.2%, +80 bps YoY |
| Operating EBITDA (excl. ESOP) | ₹292 cr, +20% YoY |
| Operating EBITDA margin (excl. ESOP) | 29%, +190 bps YoY |
| Profit after tax | ₹177 cr, +25% YoY |
| Employee cost (incl. ESOP) | ₹167 cr, +12% YoY |
| ESOP cost | 4% of reported EBITDA vs 5% YoY |
| Other expense as % of sales | improved by 130 bps YoY |
| Gross debt | ₹108 cr, reduced from ₹357 cr as of 31 Mar 2024 |
| Net cash position | ₹313 cr |
| Domestic volume growth (IQVIA) | +4%, 300 bps above IPM volume growth |
| Domestic growth breakdown | +4% volume, ~6% price, ~2% new introductions |
| Domestic organic growth (excl. Ophthalmology) | +13% YoY |
| Ophthalmology portfolio annualized run rate | ₹180 cr+ expected in FY25, up from ~₹160 cr last year |
| Sporlac brand revenue | ₹100 cr, 20% CAGR over 3 years |
| Razel franchise revenue | ₹89 cr, +29% as per IQVIA MAT Jun 2024 |
| Azmarda monthly demand | 120,000–125,000 units steady state |
| CDMO growth outlook | double-digit growth expected for FY25, pickup from Sep onwards |
| Operating EBITDA margin guidance | 26% to 28%, expected on higher side |
| Domestic growth guidance | 12% to 14% (mid-teens) |
| Interest cost expected for Q2 FY25 | ~₹3 cr, down from ₹6 cr in Q1 |
| ESOP charge guidance for FY25 | ₹42–45 cr |